Adalimumab
Brand name: Humira(Cf) Pen
Rank #6 of 500 drugs by total cost
$2.17B
Total Cost
240,925
Total Claims
$2.17B
Total Cost
7,894
Prescribers
$8,997
Cost per Claim
11,221
Beneficiaries
252,309
30-Day Fills
$275K
Avg Cost/Provider
31
Avg Claims/Provider
About Adalimumab
Adalimumab (sold as Humira(Cf) Pen) was prescribed 240,925 times by 7,894 Medicare Part D providers in 2023, costing the program $2.17B. At $8,997 per claim, this is a high-cost medication.
💰 This drug alone accounts for 0.8% of all Medicare Part D drug spending.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 3 | Empagliflozin (Jardiance) | $3.58B | 3,334,784 |
| 4 | Dulaglutide (Trulicity) | $2.99B | 2,175,100 |
| 5 | Rivaroxaban (Xarelto) | $2.45B | 2,628,123 |
| 6 | Adalimumab (Humira(Cf) Pen) | $2.17B | 240,925 |
| 7 | Lenalidomide (Revlimid) | $2.15B | 130,834 |
| 8 | Insulin Glargine,hum.Rec.Anlog (Lantus Solostar) | $1.94B | 3,118,259 |
| 9 | Fluticasone/Umeclidin/Vilanter (Trelegy Ellipta) | $1.81B | 2,046,216 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology